Correction: Neurol Ther https://doi.org/10.1007/s40120-026-00984-2
In the sentence beginning ‘Figure 2 illustrates the…’ in this article, the text ‘MSDA Test DAS ú’ should have read ‘MSDA Test DAS thresholds in detecting gadolinium enhancement’. The correct sentence should have read ‘Figure 2 illustrates the significant difference in the DAS between those with and without gadolinium enhancement (p < 0.0001), and Table 4 summarizes the performance of various MSDA Test DAS thresholds in detecting gadolinium enhancement in the setting of acute symptoms or routine disease surveillance.’
In Table 4 of this article, entries pertaining to row “≥6.5–10.0” columns “Positive predictive value (95% CI) and Negative predictive value (95% CI)” were incorrect and should have been as follows:
Positive predictive value - 87.50% (95% CI: 61.65, 98.45%)
Negative predictive value - 96.00% (95% CI: 86.29, 99.51%)
The incorrect and correct versions of Table 4 are displayed below.
Incorrect version of Table 4
Table 4.
Performance characteristics and 95% Clopper–Pearson confidence intervals (CI) of varying Octave® Disease Activity Score thresholds for predicting gadolinium-enhancing lesions
| Octave multiple sclerosis disease activity test score | Sensitivity (95% CI) |
Specificity (95% CI) |
Positive predictive value (95% CI) |
Negative predictive value (95% CI) |
Accuracy (95% CI) |
|---|---|---|---|---|---|
| > 6.0–10.0 |
100.00% (79.41%, 100.00%) |
94.00% (83.45%, 98.75%) |
84.21% (60.42%, 96.62%) |
100.00% (92.45%, 100.00%) |
95.45% (87.29%, 99.05%) |
| > 6.5–10.0 |
87.50% (61.65%, 98.45%) |
96.00% (86.29%, 99.51%) |
88% (86.29%, 99.51%) |
96% (61.65%, 98.45%) |
94% (85.20%, 98.32%) |
| > 7.0–10.0 |
75.00% (47.62%, 92.73%) |
96.00% (86.29%, 99.51%) |
85.71% (57.19%, 98.22%) |
92.31% (81.46%, 97.86%) |
90.91% (81.26%, 96.59%) |
| > 7.5–10.0 |
56.25% (29.88%, 80.25%) |
98.00% (89.35%, 99.95%) |
90.00% (55.50%, 99.75%) |
87.50% (75.93%, 94.82%) |
87.88% (77.51%, 94.62%) |
| > 8.0–10.0 |
43.75% (19.75%, 70.12%) |
98.00% (89.35%, 99.95%) |
87.50% (47.35%, 99.68%) |
84.48% (72.58%, 92.65%) |
84.85% (73.90%, 92.49%) |
| > 8.5–10.0 |
43.75% (19.75%, 70.12%) |
100.00% (92.89%, 100.00%) |
100.00% (59.04%, 100.00%) |
84.75% (73.01%, 92.78%) |
86.36% (75.69%, 93.57%) |
Correct version of Table 4
Table 4.
Performance characteristics and 95% Clopper–Pearson confidence intervals (CI) of varying Octave® Disease Activity Score thresholds for predicting gadolinium-enhancing lesions
| Octave multiple sclerosis disease activity test score | Sensitivity (95% CI) |
Specificity (95% CI) |
Positive predictive value (95% CI) |
Negative predictive value (95% CI) |
Accuracy (95% CI) |
|---|---|---|---|---|---|
| > 6.0–10.0 |
100.00% (79.41%, 100.00%) |
94.00% (83.45%, 98.75%) |
84.21% (60.42%, 96.62%) |
100.00% (92.45%, 100.00%) |
95.45% (87.29%, 99.05%) |
| > 6.5–10.0 |
87.50% (61.65%, 98.45%) |
96.00% (86.29%, 99.51%) |
87.50% (61.65%, 98.45%) |
96.00% (86.29%, 99.51%) |
93.94% (85.20%, 98.32%) |
| > 7.0–10.0 |
75.00% (47.62%, 92.73%) |
96.00% (86.29%, 99.51%) |
85.71% (57.19%, 98.22%) |
92.31% (81.46%, 97.86%) |
90.91% (81.26%, 96.59%) |
| > 7.5–10.0 |
56.25% (29.88%, 80.25%) |
98.00% (89.35%, 99.95%) |
90.00% (55.50%, 99.75%) |
87.50% (75.93%, 94.82%) |
87.88% (77.51%, 94.62%) |
| > 8.0–10.0 |
43.75% (19.75%, 70.12%) |
98.00% (89.35%, 99.95%) |
87.50% (47.35%, 99.68%) |
84.48% (72.58%, 92.65%) |
84.85% (73.90%, 92.49%) |
| > 8.5–10.0 |
43.75% (19.75%, 70.12%) |
100.00% (92.89%, 100.00%) |
100.00% (59.04%, 100.00%) |
84.75% (73.01%, 92.78%) |
86.36% (75.69%, 93.57%) |
The original article has been corrected.